Varicella zoster virus the ACIP recommended a second dose of vaccine before school entry to ensure the maintenance of high levels of varicella immunity. In 2006, the United States Food and Drug Administration approved Zostavax for the prevention of shingles. Zostavax is a more concentrated formulation of the Varivax vaccine, designed to elicit an immune response in older adults whose immunity to VZV wanes with advancing age. A systematic review by the Cochrane Library shows that Zostavax reduces the incidence of shingles by almost 50%. Shingrix is a "V. zoster" vaccine developed by GlaxoSmithKline which was approved in the United States by the
Short-term memory becomes even more difficult. However, capacity of STM can be affected by the following: Influence of long-term memory, Reading aloud, Pronunciation time and Individual differences. Diseases that cause neurodegeneration, such as Alzheimer's disease, can also be a factor in a person's short-term and eventually long-term memory. Damage to certain sections of the brain due to this disease causes a shrinkage in the cerebral cortex which disables the ability to think and recall memories. Memory loss is a natural process in aging. One study investigated whether or not there were deficits in short-term memory in older adults. This was a previous